Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

VPI-AMIKACIN DIN 02506599

Status: Dormant
Holder: VPI PHARMACEUTICALS INC
Molecule: AMIKACIN (AMIKACIN SULFATE)

Health Canada record

Active ingredient(s)AMIKACIN (AMIKACIN SULFATE) 500 MG
Dosage formSolution
RouteIntramuscular; Intravenous
SchedulePRESCRIPTION
ClassHuman
ATCJ01GB06 AMIKACIN
Original market date25-Jan-2021
Current status date13-Jul-2023
SourceHealth Canada DPD

Establishment licence of the holder

VPI Pharmaceuticals Inc — licence 102077, not currently licensed, last inspection rating C (2021-12-13).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing AMIKACIN (AMIKACIN SULFATE)

DINProductCompanyFormStrengthStatus
02173336AMIGLYDE-VZOETIS CANADA INCSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02529459AMIKACIN SULFATE INJECTIONJAMP PHARMA CORPORATIONSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02486717AMIKACIN SULFATE INJECTIONOMEGA LABORATORIES LIMITEDSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02242971AMIKACIN SULFATE INJECTION USPSANDOZ CANADA INCORPORATEDLiquidAMIKACIN (AMIKACIN SULFATE) 250 MGMarketed
02481073AMIKACIN SULFATE INJECTION USPMARCAN PHARMACEUTICALS INCSolutionAMIKACIN (AMIKACIN SULFATE) 500 MGMarketed
02539535AMIKACIN SULFATE INJECTIONJUNO PHARMACEUTICALS CORP.SolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Pre Market
02525909AMIKACIN SULFATE INJECTIONHIKMA CANADA LIMITEDSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market
00397415AMIKINBRISTOL-MYERS SQUIBB CANADASolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market
02489147ERFA-AMIKACINSEARCHLIGHT PHARMA INCSolutionAMIKACIN (AMIKACIN SULFATE) 250 MGCancelled Post Market

Notices of Compliance

NOCDateSubmissionReason
244542020-10-19Abbreviated New Drug Submission (ANDS)
Request a quote for VPI-AMIKACIN

How to read a Canadian DIN record